{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:44:33Z","timestamp":1786221873251,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-007268"],"award-info":[{"award-number":["INV-007268"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-030972"],"award-info":[{"award-number":["INV-030972"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1210558"],"award-info":[{"award-number":["OPP1210558"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1203429"],"award-info":[{"award-number":["OPP1203429"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.vaccine.2024.01.103","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T22:35:07Z","timestamp":1710801307000},"page":"2475-2484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains"],"prefix":"10.1016","volume":"42","author":[{"given":"Lizet","family":"Opmeer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Gazzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nika","family":"Ballmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Willemsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerben P.","family":"Voshol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Grudniewska-Lawton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menzo","family":"Havenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Yallop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahd","family":"Hamidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Gillissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried A.M.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.01.103_b0005","unstructured":"WHO. Two out of three wild poliovirus strains eradicated: global eradication of wild poliovirus type 3 declared on World Polio Day; 2019. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/two-out-of-three-wild-poliovirus-strains-eradicated. Accessed 07-12."},{"key":"10.1016\/j.vaccine.2024.01.103_b0010","doi-asserted-by":"crossref","first-page":"784","DOI":"10.15585\/mmwr.mm6925a4","article-title":"Progress toward polio eradication - worldwide, January 2018-March 2020","volume":"69","author":"Chard","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2024.01.103_b0015","unstructured":"Centre for Disease Control and Prevention. Progress toward polio eradication \u2014 worldwide, January 2019\u2013June 2021 | MMWR; 2021."},{"key":"10.1016\/j.vaccine.2024.01.103_b0020","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/jmv.1890320205","article-title":"Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources","volume":"32","author":"Dunn","year":"1990","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2024.01.103_b0025","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1086\/503366","article-title":"Analysis of reversions in the 5'-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines","volume":"193","author":"Laassri","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.01.103_b0030","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/infdis\/jix556","article-title":"Intestinal immune responses to type 2 oral polio vaccine (OPV) challenge in infants previously immunized with bivalent OPV and either high-dose or standard inactivated polio vaccine","volume":"217","author":"Brickley","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.01.103_b0035","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1093\/infdis\/jix108","article-title":"Lessons from the polio endgame: overcoming the failure to vaccinate and the role of subpopulations in maintaining transmission","volume":"216","author":"Thompson","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.01.103_b0040","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S1473-3099(16)30169-4","article-title":"Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants","volume":"16","author":"Wright","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.01.103_b0045","unstructured":"Global Polioeradication Initiative. cVDPV2 Outbreaks and the type 2 novel oral polio vaccine (nOPV2); 2023. https:\/\/polioeradication.org\/wp-content\/uploads\/2023\/06\/GPEI_nOPV2_Factsheet_31-May-2023.pdf. Accessed 09-01."},{"key":"10.1016\/j.vaccine.2024.01.103_b0050","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.chom.2020.04.003","article-title":"Engineering the live-attenuated polio vaccine to prevent reversion to virulence","volume":"27","author":"Yeh","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2024.01.103_b0055","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41541-020-0176-7","article-title":"Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization","volume":"5","author":"Konopka-Anstadt","year":"2020","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2024.01.103_b0060","doi-asserted-by":"crossref","first-page":"8653","DOI":"10.1128\/JVI.00370-06","article-title":"Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication","volume":"80","author":"Macadam","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.01.103_b0065","unstructured":"WHO. Roadmap for assessment of nOPV2 manufactured by PT Biofarma under the EUL procedure; 2020."},{"key":"10.1016\/j.vaccine.2024.01.103_b0070","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1016\/j.vaccine.2010.02.095","article-title":"The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox","volume":"28","author":"Heinsbroek","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.103_b0075","unstructured":"WHO. WHO technical report series No. 980, 2014, Annex 2; 2014."},{"key":"10.1016\/j.vaccine.2024.01.103_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2021.100102","article-title":"Evaluation and validation of next-generation sequencing to support lot release for a novel type 2 oral poliovirus vaccine","volume":"8","author":"Konz","year":"2021","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2024.01.103_b0085","doi-asserted-by":"crossref","first-page":"7188","DOI":"10.1016\/j.vaccine.2011.05.079","article-title":"Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV","volume":"29","author":"Bakker","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.103_b0090","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1128\/JVI.77.8.4827-4835.2003","article-title":"Complexes of poliovirus serotypes with their common cellular receptor, CD155","volume":"77","author":"He","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.01.103_b0095","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.vaccine.2018.11.020","article-title":"Evaluation of the genetic stability of Sabin strains and the consistency of inactivated poliomyelitis vaccine made from Sabin strains using direct deep-sequencing","volume":"37","author":"Deng","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.103_b0100","unstructured":"Chumakov K.M. Molecular consistency monitoring of oral poliovirus vaccine and other live viral vaccines. Dev Biol Stand 1999;100:67\u201374. PMID: 10616177."},{"key":"10.1016\/j.vaccine.2024.01.103_b0105","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1073\/pnas.88.1.199","article-title":"Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine","volume":"88","author":"Chumakov","year":"1991","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2024.01.103_b0110","article-title":"Quantitative RT-PCR assays for quantification of undesirable mutants in the novel type 2 oral poliovirus vaccine","volume":"10","author":"Manukyan","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.01.103_b0115","doi-asserted-by":"crossref","unstructured":"Guo Y, Li J, Li CI, Long J, Samuels DC, Shyr Y. The effect of strand bias in Illumina short-read sequencing data. BMC Genomics. 2012 Nov 24;13:666. https:\/\/doi.org\/10.1186\/1471-2164-13-666.","DOI":"10.1186\/1471-2164-13-666"},{"key":"10.1016\/j.vaccine.2024.01.103_b0120","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1006\/viro.1995.1420","article-title":"Microevolution of type 3 Sabin strain of poliovirus in cell cultures and its implications for oral poliovirus vaccine quality control","volume":"211","author":"Rezapkin","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2024.01.103_b0125","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1006\/viro.1995.1268","article-title":"Genetic stability and mutant selection in Sabin 2 strain of oral poliovirus vaccine grown under different cell culture conditions","volume":"209","author":"Taffs","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2024.01.103_b0130","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41541-021-00355-y","article-title":"Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses","volume":"6","author":"Wahid","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2024.01.103_b0135","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41541-022-00437-5","article-title":"Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children","volume":"7","author":"Wahid","year":"2022","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2024.01.103_b0140","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/clinchem\/hvab052","article-title":"Efficiency correction is required for accurate quantitative PCR analysis and reporting","volume":"67","author":"Ruijter","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.vaccine.2024.01.103_b0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1586\/14737159.3.1.27","article-title":"Single nucleotide polymorphism genotyping using locked nucleic acid (LNA\u2122)","volume":"3","author":"Mouritzen","year":"2003","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.vaccine.2024.01.103_b0150","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1128\/AEM.03039-05","article-title":"Improved in situ hybridization efficiency with locked-nucleic-acid-incorporated DNA probes","volume":"72","author":"Kubota","year":"2006","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.vaccine.2024.01.103_b0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003701","article-title":"Locked nucleic acid pentamers as universal PCR primers for genomic DNA amplification","volume":"3","author":"Sun","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.01.103_b0160","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/humu.10228","article-title":"Enhanced allele-specific PCR discrimination in SNP genotyping using 3\u2032 locked nucleic acid (LNA) primers","volume":"22","author":"Latorra","year":"2003","journal-title":"Hum Mutat"},{"key":"10.1016\/j.vaccine.2024.01.103_b0165","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ab.2003.09.003","article-title":"Real-time genotyping with oligonucleotide probes containing locked nucleic acids","volume":"324","author":"Ugozzoli","year":"2004","journal-title":"Anal Biochem"},{"key":"10.1016\/j.vaccine.2024.01.103_b0170","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1111\/1751-7915.14031","article-title":"Sequential development of several RT-qPCR tests using LNA nucleotides and dual probe technology to differentiate SARS-CoV-2 from influenza A and B","volume":"15","author":"Radv\u00e1nszka","year":"2022","journal-title":"J Microbial Biotechnol"},{"key":"10.1016\/j.vaccine.2024.01.103_b0175","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jmoldx.2010.11.005","article-title":"Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping","volume":"13","author":"Arcila","year":"2011","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.vaccine.2024.01.103_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036084","article-title":"Allele specific locked nucleic acid quantitative PCR (ASLNAqPCR): an accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutation","volume":"7","author":"Morandi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.01.103_b0185","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/101894","article-title":"Multiplex degenerate primer design for targeted whole genome amplification of many viral genomes","volume":"2014","author":"Gardner","year":"2014","journal-title":"Adv Bioinforma"},{"key":"10.1016\/j.vaccine.2024.01.103_b0190","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1038\/s41598-023-31871-7","article-title":"LNA blockers for improved amplification selectivity","volume":"13","author":"Prout","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2024.01.103_b0195","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s42003-021-01751-9","article-title":"PANDAA intentionally violates conventional qPCR design to enable durable, mismatch-agnostic detection of highly polymorphic pathogens","volume":"4","author":"MacLeod","year":"2021","journal-title":"Commun Biol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24001300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24001300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:21:22Z","timestamp":1786220482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24001300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0264410X24001300"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.103","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}